Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Tlco Holdings Inc. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The data shows 2 pending office actions distributed across 2 distinct examiners. This distribution indicates that the company is managing multiple independent prosecution tracks simultaneously, rather than a single consolidated effort. The prosecution activity is spread across 2 distinct art units, reflecting a breadth of technical subject matter within the biotechnology sector.
The busiest examiner for this portfolio is CAIN, JENNIFER LYNN, who is currently handling 1 busiest examiner pending action. This count shows that the workload is evenly divided, as the busiest examiner is responsible for 1 of the 2 total pending office actions. Because there are 2 distinct examiners, the company must navigate different examination styles and preferences. This distribution of 2 pending office actions across multiple art units requires a coordinated strategy to ensure consistency across the Biotechnology & Pharmaceuticals filings.
Practitioners should note that the presence of 2 distinct examiners and 2 distinct art units prevents any single USPTO official from dominating the portfolio's direction. The 1 busiest examiner pending action assigned to CAIN, JENNIFER LYNN represents a balanced approach to portfolio management. This structure provides Tlco Holdings Inc. with a broader exposure to USPTO personnel than a more concentrated portfolio, though it requires monitoring 2 different sets of examiner behaviors.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CAIN, JENNIFER LYNN | 1 | 45.0% | +70.0% |
| KERSHAW, KELLY P | 1 | 17.7% | +16.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18097370 | CANNABIS AND MUSHROOM COMPOUNDS INFUSED CONSUMABLES | CAIN, JENNIFER LYNN | 12d |
| 17953248 | Food Compounds Infused Consumables | KERSHAW, KELLY P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18097370 | CANNABIS AND MUSHROOM COMPOUNDS INFUSED CONSUMABLES | CAIN, JENNIFER LYNN | 12d |
| 17953248 | Food Compounds Infused Consumables | KERSHAW, KELLY P | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18097370 | CANNABIS AND MUSHROOM COMPOUNDS INFUSED CONSUMABLES | CAIN, JENNIFER LYNN | 1655 | §103§112 | Final Rejection | 12d | Pending | Jan 16, 2023 |
| 17953248 | Food Compounds Infused Consumables | KERSHAW, KELLY P | 1791 | §103Other | Non-Final OA | — | Pending | Sep 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial